Aim: Genomically matched trials in primary brain tumors (PBTs) require recent tumor sequencing. We evaluated whether circulating tumor DNA (ctDNA) could facilitate genomic interrogation in these patients. Methods: Data from 419 PBT patients tested clinically with a ctDNA NGS panel at a CLIA-certified laboratory were analyzed. Results: A total of 211 patients (50%) had ≥1 somatic alteration detected. Detection was highest in meningioma (59%) and gliobastoma (55%). Single nucleotide variants were detected in 61 genes, with amplifications detected in ERBB2, MET, EGFR and others. Conclusion: Contrary to previous studies with very low yields, we found half of PBT patients had detectable ctDNA with genomically targetable off-label or clinical trial options for almost 50%. For those PBT patients with detectable ctDNA, plasma cfDNA genomic analysis is a clinically viable option for identifying genomically driven therapy options.
Piccioni, David E; Achrol, Achal Singh; Kiedrowski, Lesli A; Banks, Kimberly C; Boucher, Najee; Barkhoudarian, Garni; Kelly, Daniel F; Juarez, Tiffany; Lanman, Richard B; Raymond, Victoria M; Nguyen, Minhdan; Truong, Judy D; Heng, Annie; Mini Gill, Jaya; Saria, Marlon G; Pingle, Sandeep C; and Kesari, Santosh, "Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors." (2019). Articles, Abstracts, and Reports. 2661.